Multi-kinase-IN-4

Multi-kinase-IN-4

• UNSPSC Description: Multi-kinase-IN-4 (compound 5d) is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC50 values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. Multi-kinase-IN-4 shows broad-spectrum anti-cancer activities against HepG2, MCF-7, MDA-231, and HeLa cell lines (IC50 = 1.94–7.1 µM), but exhibits lower toxicity in the WI-38 cells (IC50 = 40.85 µM). Multi-kinase-IN-4 induces apoptosis and arrests cell cycle at S phase in HepG2 cells. Multi-kinase-IN-4 has the potential for the research of cancer[1].
• Target Antigen: Apoptosis; CDK; EGFR; Necroptosis; VEGFR
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/multi-kinase-in-4.html
• Solubility: 10 mM in DMSO
• Smiles: O=C1N(C/C=C(CC)\C)C(SCC2=CC=C(Cl)C=C2)=NC3=C1C=C(F)C=C3
• Molecular Weight: 402.91
• References & Citations: [1]Ali Altharawi, et al. Novel 2-Sulfanylquinazolin-4(3H)-one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study. Molecules. 2023 Jul; 28(14): 5548.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported